Science review: Apoptosis in acute lung injury by Matute-Bello, Gustavo & Martin, Thomas R
355
ARDS = acute respiratory distress syndrome; BAL = bronchoalveolar lavage; GM-CSF = granulocyte/macrophage colony-stimulating factor; IL =
interleukin; SP-A = surfactant protein A.
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Apoptosis is a process of controlled cellular death whereby
the activation of specific death-signaling pathways leads to
deletion of cells from tissue. These death-signaling pathways
can be activated in response to receptor–ligand interactions,
environmental factors such as ultraviolet light and redox
potential, and internal factors that are encoded in the genome
(‘programmed cell death’). Ultimately, apoptosis results in
fragmentation of the DNA, a decrease in cell volume, and
phagocytosis of the apoptotic cell by nearby phagocytes.
Inappropriate activation or inhibition of apoptosis can lead to
human disease either because ‘undesired’ cells develop pro-
longed survival or because ‘desired’ cells die prematurely. In
addition, phagocytosis of some apoptotic cells, such as neu-
trophils, can induce changes in the activation phenotype of
lung macrophages [1]. The importance of apoptosis resides
in the fact that several steps that are involved in its modula-
tion are susceptible to therapeutic intervention.
Two main hypotheses that link apoptosis with the pathogenesis
of acute respiratory distress syndrome (ARDS) have been pos-
tulated, namely the ‘neutrophilic hypothesis’ and the ‘epithelial
hypothesis’. The former hypothesis suggests that neutrophil
apoptosis plays an important role in the resolution of inflamma-
tion, and predicts that inhibition of neutrophil apoptosis or inhibi-
tion of clearance of apoptotic neutrophils is deleterious in ARDS
[2,3]. The epithelial hypothesis suggests that the epithelial injury
seen during ARDS is associated with apoptotic death of alveo-
lar epithelial cells in response to soluble mediators such as
soluble Fas ligand, and predicts that blockade of such inhibitors
may be beneficial in preventing or treating ARDS [4,5]. These
two hypotheses are not mutually exclusive, and both could play
an important role in the pathogenesis of ARDS. In the present
review we evaluate the evidence supporting each of these two
hypotheses, with emphasis on the main modulatory steps that
are candidates for therapeutic intervention.
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Abstract
Apoptosis is a process of controlled cellular death whereby the activation of specific death-signaling
pathways leads to deletion of cells from tissue. The importance of apoptosis resides in the fact that
several steps involved in the modulation of apoptosis are susceptible to therapeutic intervention. In the
present review we examine two important hypotheses that link apoptosis with the pathogenesis of
acute lung injury in humans. The first of these, namely the ‘neutrophilic hypothesis’, suggests that
during acute inflammation the cytokines granulocyte colony-stimulating factor and
granulocyte/macrophage colony-stimulating factor prolong the survival of neutrophils, and thus
enhance neutrophilic inflammation. The second hypothesis, the ‘epithelial hypothesis’, suggests that
epithelial injury in acute lung injury is associated with apoptotic death of alveolar epithelial cells
triggered by soluble mediators such as soluble Fas ligand. We also review recent studies that suggest
that the rate of clearance of apoptotic neutrophils may be associated with resolution of neutrophilic
inflammation in the lungs, and data showing that phagocytosis of apoptotic neutrophils can induce an
anti-inflammatory phenotype in activated alveolar macrophages.
Keywords adult respiratory distress syndrome, apoptosis, epithelial cells, inflammation, neutrophils356
Critical Care    October 2003 Vol 7 Matute-Bello and Martin
Neutrophil apoptosis and acute lung injury
Neutrophil apoptosis affects the pathogenesis or resolution of
acute lung injury by three main mechanisms. The first mecha-
nism relates to the rate at which neutrophils become apop-
totic, and how this rate is influenced by soluble mediators that
are present in the inflammatory microenvironment. The second
mechanism pertains to the clearance of apoptotic neutrophils
by surrounding phagocytes, and how changes in this clear-
ance rate affect the resolution of inflammation. The third mech-
anism is related to how phagocytosis of apoptotic neutrophils
affects the activation phenotype of phagocytic cells, poten-
tially changing it from proinflammatory to anti-inflammatory.
Rate of neutrophil apoptosis and acute lung injury
Studies in humans have shown that bronchoalveolar lavage
(BAL) fluids from patients with early ARDS inhibit the rate at
which neutrophils develop apoptosis in vitro [6]. This
inhibitory effect disappears at later stages of ARDS, as
inflammation resolves. The inhibitory effect of BAL fluids on
neutrophil apoptosis is mediated by soluble factors, primarily
the proinflammatory cytokines granulocyte colony-stimulating
factor and granulocyte/macrophage colony-stimulating factor
(GM-CSF), and possibly IL-8 and IL-2 [7–10]. However, the
importance of inhibition of neutrophil apoptosis in ARDS is
debated because there is no clear association between the
ability of BAL fluids to induce neutrophil apoptosis and the
outcome of patients with ARDS, or progression to ARDS in
patients who are at risk for the disease [6]. In fact, the
patients who survive have higher concentrations of GM-CSF
in their BAL fluids [6]. The lack of association between sur-
vival and inhibition of neutrophil apoptosis in humans does
not necessarily mean that modulation of neutrophil apoptosis
is irrelevant to the pathogenesis and resolution of inflamma-
tion during ARDS. This is because survival in human ARDS is
affected by many factors that are difficult to control, including
the presence of other diseases (e.g. diabetes, heart disease,
chronic obstructive pulmonary disease) and ventilatory strate-
gies, among other factors. Therefore, the importance of mod-
ulation of neutrophil apoptosis in the pathogenesis of acute
lung injury has been studied using animal models.
Parsey and coworkers [11] measured the proportion of apop-
totic neutrophils in the lungs of mice over 48 hours after
endotoxemia or hemorrhage. Apoptosis was measured using
the cell surface marker annexin-V in neutrophils isolated from
the lung parenchyma. Immediately after hemorrhage or endo-
toxemia, the proportion of apoptotic neutrophils was
18.5±1.9%. This proportion decreased significantly 1 hour
after the insult, remained low for 24 hours, and returned to
baseline at 48 hours. That study confirms the human observa-
tions suggesting that neutrophil apoptosis is inhibited early in
inflammation but it does not clarify the role played by neu-
trophil apoptosis inhibition in the pathogenesis of the injury.
This question was addressed in a subsequent study that
investigated whether enhancement of neutrophil apoptosis
attenuates lung injury in a murine model of ischemia/reperfu-
sion. Sookhai and coworkers [12] demonstrated that
aerosolization of opsonized killed Escherichia coli enhanced
neutrophil apoptosis in the lungs of mice. They then showed
that the mortality and the lung injury that follows
ischemia/reperfusion decreased significantly when neutrophil
apoptosis was enhanced by aerosolization of dead E coli.
That study suggests that in acute lung injury enhancement of
neutrophil apoptosis is beneficial to the host.
Clearance of apoptotic neutrophils and acute lung injury
The studies cited thus far focused on identifying associations
between the rate at which neutrophils become apoptotic and
the pathogenesis of acute lung injury. Clearance of apoptotic
cells by phagocytes also plays a role in survival and persistence
of inflammation during acute lung injury [13]. Macrophages and
other phagocytic cells recognize apoptotic cells via a number
of membrane surface molecules. One of these membrane mol-
ecules, namely CD44, appears to play an important role in the
clearance of apoptotic neutrophils in vivo and in vitro [14,15].
Teder and coworkers [14] demonstrated that mice deficient in
CD44 failed to clear apoptotic neutrophils in a model of
bleomycin-induced lung injury. Failure to clear apoptotic neu-
trophils was associated with worsened inflammation and
increased mortality. Adoptive transfer of normal marrow cells
into the CD44-deficient mice reversed the defect in apoptotic
cell clearance and improved survival. However, CD44 can
increase the synthesis of chemokines such as IL-8 by enhanc-
ing clearance of the glycosaminoglycan hyaluronan [16], and it
is not possible to determine whether the improvement in
outcome in this model of lung injury was due to the effects of
CD44 on clearance of apoptotic neutrophils or to the effect of
CD44 on chemokine production.
Additional studies conducted by Hussain and coworkers [17]
support the hypothesis that the rate of clearance of apoptotic
neutrophils is important for the resolution phase of lung injury.
Those investigators showed that the resolution of oleic-acid-
induced lung injury in rats is associated with generalized apop-
tosis of neutrophils and with uptake of apoptotic neutrophils
by alveolar macrophages, but the data did not show a defini-
tive causal relationship. Further studies are needed to demon-
strate conclusively that changes in the rate of clearance of
apoptotic neutrophils can affect outcome in acute lung injury.
Phagocytosis of apoptotic neutrophils and release of
cytokines by macrophages
The third mechanism whereby apoptosis of neutrophils can
modify the inflammatory response is by modulating the pro-
duction of proinflammatory cytokines by alveolar macro-
phages. Phagocytosis of apoptotic neutrophils by
macrophages inhibits macrophage production of proinflam-
matory cytokines (i.e. IL-1β, IL-8, IL-10, GM-CSF, and tumor
necrosis factor-α) and increases release of anti-inflammatory
mediators (i.e. transforming growth factor-β1, prostaglandin
E2, and platelet-activating factor) [1,18]. These findings raise357
the possibility that increases in phagocytosis of apoptotic
neutrophils could favor resolution of inflammation by down-
regulating the inflammatory phenotype in activated alveolar
macrophages.
Epithelial cell apoptosis in the pathogenesis
of acute lung injury
In addition to neutrophil alveolitis, the main features of ARDS
include destruction of the alveolar epithelium, with severe
damage to the alveolar capillary barrier and major increases in
alveolar capillary permeability. In studies investigating the mor-
phologic changes that occur early in human ARDS, Bachofen
and Weibel [19] noted that, early in the course of ARDS,
type I pneumocytes exhibit decreased size and condensation
of the chromatin. The alveolar epithelium of patients who die
from lung injury contains cells that exhibit evidence of DNA
fragmentation [20], and alveolar pneumocytes from humans
with diffuse alveolar damage show upregulation of Bax, a
Bcl-2 analog that favors apoptosis [21]. Evidence of extensive
alveolar epithelial cell apoptosis has been described in murine
models of pulmonary fibrosis and lipopolysaccharide-induced
lung injury [22–25]. Apoptosis of alveolar epithelial cells is
detectable in mice as early as 6 hours after intratracheal
administration of lipopolysaccharide [25].
The mechanisms that are responsible for epithelial cell apop-
tosis in acute lung injury are incompletely understood, but
several lines of evidence point to the Fas/Fas ligand system
[4,22,26,27]. The Fas/Fas ligand system is comprised of the
cell membrane surface receptor Fas (CD95) and its natural
ligand, namely Fas ligand [28]. Fas ligand exists in a mem-
brane bound form and a soluble form, both of which are
capable of inducing apoptosis of susceptible cells [4,27].
Alveolar and airway epithelial cells express Fas on their
surface [29–31], and the expression of Fas in epithelial cells
increases in response to inflammatory mediators such as
lipopolysaccharide [22].
The soluble form of Fas ligand has been detected in several
human lung diseases, including pulmonary fibrosis, bronchi-
olitis obliterans with organizing pneumonia, and ARDS
[4,32,33]. In humans with early ARDS, soluble Fas ligand is
present in the BAL fluid, and reaches higher concentrations
in the lung fluids from patients who die [4]. The Fas ligand
present in the lung fluids from patients with ARDS is biologi-
cally active and can induce apoptosis in normal human distal
lung epithelial cells.
Several factors modulate Fas-mediated apoptosis of alveolar
epithelial cells. Surfactant protein A (SP-A), the primary
protein present in pulmonary surfactant, is an inhibitor of
type II apoptosis in vivo [34,35]. This is important because, in
patients with early ARDS, the concentration of SP-A is
decreased in BAL fluid [36]. The lower concentration of SP-A
would favor apoptosis of type II cells in these patients.
Another important modulator of Fas ligand in the lungs is
angiotensin II. Epithelial cells interact with angiotensin II via
the angiotensin receptor subtype AT1, and this interaction is
required for Fas-mediated apoptosis of alveolar epithelial
cells in vitro [37]. In ARDS the concentration of angiotensin-
converting enzyme, which catabolizes the conversion of
angiotensin I to angiotensin II, is increased in BAL fluid [38].
Therefore, in early ARDS a combination of three factors
favors alveolar epithelial apoptosis: increased concentrations
of soluble Fas ligand; decreased concentrations of SP-A; and
increased concentrations of angiotensin-converting enzyme
and angiotensin II.
Several lines of research in animals support the hypothesis
that activation of the Fas/Fas ligand system is important in the
pathogenesis of acute lung injury. Administration of the
monoclonal antibody Jo2, which binds and activates Fas,
results in alveolar epithelial cell apoptosis, neutrophilic lung
inflammation, and permeability changes in mice [27]. A single
administration of Jo2 is followed 6 and 24 hours later by
changes in alveolar permeability and neutrophil recruitment,
whereas chronic administration of Jo2 leads to the develop-
ment of pulmonary fibrosis [27,33]. This phenomenon is
associated with evidence of DNA fragmentation in cells of the
alveolar epithelium [27]. Human recombinant Fas ligand can
also induce lung injury in animals. In rabbits, human recombi-
nant Fas ligand at low doses produces neutrophilic alveolitis
and permeability changes, whereas higher doses result in
hemorrhagenic lung injury [26]. Thus, activation of the
Fas/Fas ligand system in vivo is associated with two phenom-
ena: the first is apoptosis of the alveolar epithelium with
epithelial damage and increased alveolar permeability; and
the second is increasing inflammatory cytokines and neu-
trophil recruitment.
Conclusion
A growing body of evidence implicates apoptosis in the
pathogenesis and resolution of ARDS. Studies in humans
and animals suggest that neutrophil apoptosis is inhibited
early in ARDS and that the lifespan of neutrophils returns to
normal as inflammation resolves. Furthermore, the rate of
clearance of apoptotic neutrophils may play an important role
in the resolution of the inflammatory response. Apoptosis of
cells of the alveolar epithelium mediated by the Fas/Fas
ligand system may also be of particular importance in the
development of the permeability changes that are character-
istic of ARDS. Further research is necessary to identify anti-
apoptotic therapeutic targets that may be useful in the
treatment of human ARDS.
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